Loading clinical trials...

Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma | Clinical Trials | Clareo Health

RECRUITINGPHASE2

Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma

Azacitidine Plus PD-1 Therapy for Relapsed/Refractory Hodgkin Lymphoma

NCT06190067•Navy General Hospital, Beijing

Summary

The goal of this phase 2 trial is to test the safety and efficacy of azacitidine when given together with PD-1 therapy in treating patients with relapsed/refractory classic Hodgkin lymphoma.

Detailed Description

The investigators will evaluate response rate, progression free survival (PFS), overall survival (OS), and toxicity of azacytidine combined with PD-1 therapy in classic relapsed/refractory Hodgkin lymphoma.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Pathologically confirmed Hodgkin Lymphoma according World Health Organization (WHO) classification.
•Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).
•Patient must understand and voluntarily sign an ICF prior to any study-specific assessments/procedures being conducted.
•Patient is willing and able to adhere to the study visit schedule and other protocol requirements.
•Meet the following lab criteria: Absolute Neutrophil Count (ANC) ≥ 1,5 x 10\^9/L (≥ 1 x 10\^9/L if bone marrow (BM) involvement by lymphoma); Platelet ≥ 75 x 10\^9/L (≥ 50 x 10\^9/L if BM involvement by lymphoma); Hemoglobin ≥ 8 g/dL.
•Anticipated life expectancy at least 3 months.

Exclusion Criteria

•Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.
•Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.
•Pregnant or lactating women.

Locations (1)

Navy General Hospital

Beijing, Beijing Municipality, China

Key Dates

Start Date

October 30, 2023

Primary Completion Date

December 1, 2026

Completion Date

December 1, 2028

Last Updated

January 30, 2024

Enrollment

ESTIMATED participants

Conditions

Relapsed Classic Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma

Interventions

Azacitidine Plus PD-1 therapy

DRUG

Contacts

Liren Qian, PhD

CONTACT

+861066947192 qlr2007@126.com

Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

NCT04561206

Relapsed Classic Hodgkin Lymphoma

View study

COMPLETEDPHASE1

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

NCT02595866

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 30, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions